In vivo delivery of LNPs, AAV, and non-viral platforms in small and large animal models

The development of efficient and safe delivery systems is a cornerstone of gene therapy and genome editing. Lipid nanoparticles (LNPs), adeno-associated viral (AAV) vectors, and non-viral platforms have emerged as leading modalities for in vivo delivery of nucleic acids and gene editing components, each offering distinct advantages in terms of payload capacity, immunogenicity, tissue tropism, and manufacturability.While much of the early work in this field has relied on small animal models, translating these findings to large animal models remains a critical and challenging step toward clinical application. Large animals present physiological, immunological, and anatomical complexities that more closely mirror the human context, making them indispensable for assessing delivery efficiency, safety, and biodistribution at a clinically relevant scale.This Research Topic aims to bring together original research, reviews, and perspectives exploring the in vivo performance of LNPs, AAV vectors, and non-viral delivery platforms across both small and large animal models. We welcome contributions addressing delivery optimization, tissue-specific targeting, immune responses, toxicology, and the translational challenges of scaling delivery systems from bench to bedside. Studies integrating comparative analyses between animal models are particularly encouraged. Topic editors: Marina Stavrou, Alexia Kagiava, Suzan S. Boutary Source: https://www.frontiersin.org/research-topics/80994/in-vivo-delivery-of-lnps-aav-and-non-viral-platforms-in-small-and-large-animal-models